ASX Article

TruScreen’s Chief Executive Officer, Dr Beata Edling, recently spoke with ASX Consulting Editor, Tony Featherstone.   |   Read the full article on the ASX website

“Edling says the ASX listing has increased TruScreen’s international visibility. “This is very important in the biotech sector. As TruScreen grows, we will need to access a wider range of collaborations with global pharmaceutical and medtech companies that focus on ASX-listed entities. TruScreen’s liquidity needs will also change. Being dual listed on a global bourse, such as ASX, provides greater access to international investors.”